Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aumolertinib with or without radiotherapy in treatment-naïve EGFR-mutated oligometastatic NSCLC
ChiCTR2600121546Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of almonertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600121546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121546.